Canine transitional cell carcinoma is a malignant tumor that develops in the bladder, and early diagnosis along with proper management are key to improving survival rates. We’ve compiled recommended products and selection criteria to support treatment and enhance your dog’s quality of life.





| Item | BEST 1 | BEST 2 | BEST 3 |
|---|---|---|---|
| Main ingredients | Antioxidants, immune modulators, liver-protective ingredients | Blueberry, omega-3, resveratrol | Silymarin, glutathione, immune activators |
| Formulation | Powder | Liquid | Capsule |
| Ease of administration | High | Very high | Moderate |
| Claimed purpose | Immune/liver support | Antioxidant/anti-inflammatory | Liver support/immune support |
| Veterinarian-recommended | True | False | True |
The effects listed in the table are claims made by the products; supplements are adjuncts, not treatments. In particular, antioxidant ingredients may reduce treatment efficacy, and there is a recommendation to avoid high-dose intake during treatment, so be sure to choose only after consulting your veterinarian. The appropriate product differs depending on the treatment stage.
Caution: Adverse Effects May Occur with Overdosing
When using nutritional supplements for transitional cell carcinoma, it is important to follow the dosage recommended by your veterinarian. Overdosing can cause nausea, diarrhea, and liver dysfunction. Dogs with compromised liver function require particular caution. If any adverse symptoms occur during use, discontinue the supplement immediately and consult your veterinarian.


A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.
Share
[1] Jubb, K. et al. (1993). Veterinary Surgical Oncology, 2nd Ed. Elsevier Saunders.
[2] Moore, A.S. et al. (2002). Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases. J Am Vet Med Assoc, 221:811–818.
[3] Birchard, S.J. et al. (1986). Nonlymphoid intestinal neoplasia in 32 dogs and 14 cats. J Am Anim Hosp Assoc, 22:533–537.